Last Updated: May 6, 2026

SACUBITRIL Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Sacubitril, and when can generic versions of Sacubitril launch?

Sacubitril is a drug marketed by Alembic, Alkem Labs Ltd, Biocon Pharma, Crystal, Dr Reddys, Hetero Labs Ltd Iii, Laurus, Lupin, Macleods Pharms Ltd, MSN, Novugen Pharma Sdn, Somerset Theraps Llc, Torrent, and Zydus Pharms. and is included in fourteen NDAs.

The generic ingredient in SACUBITRIL is sacubitril; valsartan. There are eleven drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the sacubitril; valsartan profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sacubitril

A generic version of SACUBITRIL was approved as sacubitril; valsartan by ALEMBIC on May 28^th, 2024.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for SACUBITRIL?
What are the global sales for SACUBITRIL?
What is Average Wholesale Price for SACUBITRIL?

Summary for SACUBITRIL

US Patents:	0
Applicants:	14
NDAs:	14
DailyMed Link:	SACUBITRIL at DailyMed

Drug patent expirations by year for SACUBITRIL

US Patents and Regulatory Information for SACUBITRIL

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Pharms	SACUBITRIL AND VALSARTAN	sacubitril; valsartan	TABLET;ORAL	213719-002	Jul 9, 2024	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Novugen Pharma Sdn	SACUBITRIL AND VALSARTAN	sacubitril; valsartan	TABLET;ORAL	213611-002	Jul 16, 2025	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Msn	SACUBITRIL AND VALSARTAN	sacubitril; valsartan	TABLET;ORAL	213748-001	Jul 16, 2025	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Novugen Pharma Sdn	SACUBITRIL AND VALSARTAN	sacubitril; valsartan	TABLET;ORAL	213611-003	Jul 16, 2025	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Msn	SACUBITRIL AND VALSARTAN	sacubitril; valsartan	TABLET;ORAL	213748-002	Jul 16, 2025	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Alembic	SACUBITRIL AND VALSARTAN	sacubitril; valsartan	TABLET;ORAL	213682-001	May 28, 2024	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hetero Labs Ltd Iii	SACUBITRIL AND VALSARTAN	sacubitril; valsartan	TABLET;ORAL	213668-003	Jul 17, 2025	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.